Completed PHASE4 INTERVENTIONAL 2-arm NCT02869321

Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy (ANTALGIP)

Evaluation of Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy

Sponsor: Central Hospital, Nancy, France

Conditions Breakthrough Pain Gastrostomy Upper Aerodigestive Tract Neoplasms

Interventions Fentanyl Fentanyl placebo Gastrostomy Morphine Sulfate Morphine Sulfate placebo

Updated 7 times since 2017 Last updated: May 10, 2019 Started: May 31, 2015 Primary completion: May 31, 2018 Completion: May 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Breakthrough Pain and Gastrostomy, this trial is completed. The trial is conducted by Central Hospital, Nancy, France and has accumulated 7 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Sep 2018 — Jun 2019 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central Hospital, Nancy, France

Data source: Central Hospital, Nancy, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nancy, France